{"entity":{"id":"rp-1664","kind":"drug","name":"RP-1664","aka":[],"tldr":"RP-1664 is an experimental oral small molecule kinase inhibitor from Repare Therapeutics, in phase 1 trials for advanced solid tumours, with and without TRIM37 amplification; its current status is not stated.","summary":"RP-1664 is an oral small molecule kinase inhibitor from Repare Therapeutics. A first-in-class, highly selective oral inhibitor of Polo-like kinase 4 (PLK4), a synthetic-lethal target linked to TRIM37 overexpression. Its furthest stage is phase 1, for advanced solid tumours, with and without TRIM37 amplification. ClinicalTrials.gov registers it in one study linked below. Phase 1 LIONS NCT06232408 terminated ('Sponsor decided to terminate study early'). Preliminary data were presented at the AACR-NCI-EORTC meeting in October 2025. In November 2025 Repare said it was trying to license or dispose of the programme; Repare was acquired by XenoTherapeutics in January 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Repare Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525159942/d944012dex991.htm"},{"label":"Repare Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525283314/d39095dex991.htm"},{"label":"Repare Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06232408"},{"label":"ClinicalTrials.gov: trials of RP-1664","url":"https://clinicaltrials.gov/search?intr=RP-1664"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["plk4"],"drugs":[],"companies":["repare-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06232408"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"RP-1664","modality":"Oral small molecule kinase inhibitor","mechanism":"A first-in-class, highly selective oral inhibitor of Polo-like kinase 4 (PLK4), a synthetic-lethal target linked to TRIM37 overexpression.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rp-1664/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"plk4","kind":"target","name":"PLK4","route":"/targets/plk4/"}],"company":[{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/"}],"trial":[{"id":"nct06232408","kind":"trial","name":"LIONS (PLK4 Inhibitor in Advanced Solid Tumors)","route":"/trials/nct06232408/"}]}}